Please assess the completion status of the following clinical trial:

Trial Title: Randomized Phase II Trial of Doxil With or Without Dexamethasone for Metastatic Hormone Refractory Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with metastatic hormone refractory prostate cancer as defined by resistance to both ablative therapy (with either LHRH agonists or orchiectomy) \& anti-androgens.~2. Patients must have symptoms related to disease.~3. Patients must have PS 0,1,2 (ECOG).~4. Patients must have measurable disease (RECIST) or PSA \> 5.~5. Patients must have adequate organ function as defined as follows: leukocytes \>/= 3,000/mm3, absolute neutrophil count \>/= 1,500/mm3, hemoglobin \>/= 8.0g/dl, platelets \>/= 100,000/mm3, serum creatinine \</= 2.5 mg/dl. Bilirubin must be \</= 2 fold above ULN. Liver transaminases (SGOT and/or SGPT) may be up to 2.5 x institutional ULN if alkaline phosphatase is \</= ULN or alkaline phosphatase may be up to 4 x ULN if transaminases are \</= ULN.~6. Patients must have a left ventricular ejection fraction (LVEF) 50% by echocardiogram~7. Patients must have failed to respond to discontinuation of anti-androgens.~8. No previous therapy with anti-androgens, corticosteroids or estrogens in the last 4 weeks.~9. Previous radiation therapy is allowed if completed at least 4 weeks prior to study entry \& therapy was cumulatively administered to \</= 25% of bone marrow.~10. Patients must be \>18 years of age~11. Patients must have an expected survival of at least 4 months.~12. Patients must have the ability to understand \& the willingness to sign a written informed consent document.~13. Patients must be willing to use adequate contraceptive method during treatment and for 3 months after completing treatment.~Exclusion Criteria:~1. Patients with previous history of cancer are excluded unless they have had curative treatment completed \>/= 5 years prior to entry onto study or had 1 of the following: in situ carcinoma (any location), basal cell carcinoma, or non-metastatic squamous cell carcinoma of the skin.~2. Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, uncontrolled diabetes mellitus, or psychiatric illness/social situations that would limit compliance with study requirements or the ability to provide informed consent.~3. Patients requiring any non study corticosteroids for any reason are excluded.~4. Patients who have received previous chemotherapy.~5. A history of cardiac disease with New York Heart Class II or greater, or clinical evidence of congestive heart failure.~6. Patients may not be receiving any other investigational agents or have participated in any investigational drug study within 4 weeks preceding initiation of treatment.~7. Major surgery within 4 weeks prior to study treatment start, or lack of complete recovery from major surgery.~8. Patients with a lack of physical integrity of the upper gastrointestinal tract or those who have malabsorption syndrome or inability to swallow tablets.~9. History of hypersensitivity reactions attributed to a conventional formulation of doxorubicin HCL or the components of Doxil®

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): dexamethasone
- 2 (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).